Genetic markers in the HLA-DQBI gene associated with an adverse hematological response to drugs
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 10, 2006
app pub date -
Feb 9, 2006
filing date -
Feb 9, 2005
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Genetic markers in the HLA-DQB1 gene associated with adverse hematological response to drug therapy are disclosed. Compositions and methods for detecting and using these HLA-DQB1 markers in a variety of clinical applications are disclosed. Such applications include methods for testing an individual for susceptibility for an adverse hematological response, methods of selecting the appropriate drug therapy for patients based on the presence or absence of a HLA-DQB1 marker, and products comprising a drug with hematological toxicity that are approved for treating patients lacking a genetic marker.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully